Metabolic Syndrome. -
Conditions
Interventions
Intervention 1: Intervention group: received two 2500 mg sachet arginine Production of pharmaceutical company Karen after lunch and dinner. Intervention 2: Control group: received 2500 mg sachet con
Placebo
Intervention group: received two 2500 mg sachet arginine Production of pharmaceutical company Karen after lunch and dinner
Control group: received 2500 mg sachet containing cellulose compounds Production of pharmaceutical company Karen after lunch and dinner
Sponsors
for research of Yazd Shahid Sadoughi University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients who agree to participate in the study? Having 3 or more of the ATP III criteria? Aged between 20 to 60. Exclusion criteria: The unwillingness of people to enter the study for any reason? Tobacco and alcohol? BMI above 35 and below 18.5? Pregnancy and lactationv hypersensitivity to the drug or allergy,Follow the special dietary? the use of insulin and Inflammatory drugs such as corticosteroids over 3 months? History of diabetes are more than 5 yearsv History of angina? stroke or heart attack in recent years? Chronic kidney disease or severe liver disease? Chronic inflammatory disease and thyroid disease during the past year? Taking any dietary supplement including L- arginine during 2 months before the start of the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Autoanalaizer. | — |
Secondary
| Measure | Time frame |
|---|---|
| HBA1C. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;Total Cholesterol. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;LDL. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;HDL. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;TG. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;INSULIN. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Enzyme colorimetry.;HOMA-IR. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Using insulin and fasting glucose.;HOMA-B. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Using insulin and fasting glucose.;QUICKI. Timepoint: at the begining of the study and 3 month after intervention. Method of measurement: Using insulin and fasting glucose. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDavood Bahrami
Yazd Shahid Sadoughi University of Medical Sciences
Outcome results
None listed